NAB-PACLITAXEL

作品数：28被引量：60H指数：5
导出分析报告
相关领域：医药卫生更多>>
相关作者：秦洁莉熊健更多>>
相关机构：包头医学院第二附属医院东南大学更多>>
相关期刊：《Journal of Pancreatology》《World Journal of Gastroenterology》《International Journal of Ophthalmology(English edition)》《Signal Transduction and Targeted Therapy》更多>>
相关基金：国家自然科学基金北京市自然科学基金中国博士后科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Nab-paclitaxel plus capecitabine as a first-line regimen for advanced biliary tract cancers:Feasible or not feasible?
《World Journal of Gastroenterology》2025年第10期134-138,共5页Jian-Qiang Chen Xiang Lan 
A clinical trial of nab-paclitaxel plus capecitabine as a first-line treatment for advanced biliary tract cancers was conducted.We analyzed the development of systemic therapy recommended by the National Comprehensive...
关键词：NAB-PACLITAXEL CAPECITABINE Biliary tract cancers Systemic therapy Firstline regimen 
Efficacy,safety,and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma:A single-arm phase 2 study
《Chinese Journal of Cancer Research》2024年第6期713-728,共16页Lin Gui Xinrui Chen Wen Zhang Zucheng Xie Yu Zhang Weihua Li Tongji Xie Jiarui Yao Haohua Zhu Le Tang Jianliang Yang Peng Liu Yan Qin Changgong Zhang Xiaohui He Yuankai Shi 
supported by the China National Major Project for New Drug Innovation(No.2017ZX09304015);the Beijing Hope Run Special Fund of the Cancer Foundation of China(No.LC2022A30);the Beijing Vlove Charity Foundation(No.JYKY2024-0200616033)。
Objective:Based on the findings of the KEYNOTE-048 study,pembrolizumab in combination with platinum and fluorouracil is the standard first-line treatment for recurrent or metastatic head and neck squamous cell carcino...
关键词：Pembrolizumab NAB-PACLITAXEL recurrent or metastatic head and neck squamous cell carcinoma Olink 
Comparison of efficacy and safety of nab-paclitaxel and oxaliplatin+S-1 and standard S-1 and oxaliplatin chemotherapy regimens for treatment of gastric cancer
《World Journal of Gastrointestinal Surgery》2024年第10期3224-3238,共15页Yi-Cong Wang Long Feng Gong-Ping Wang Peng-Jie Yu Can Guo Bao-Jia Cai Yan Song Ting Pan Bo-Hao Lin Yuan-Dong Li Jing-Jing Xiao 
Supported by The Department of Science and Technology of Qinghai Province,No.2018-SF-113;"Kunlun Talents-Plateau Famous Doctors"Project in Qinghai Province.
BACKGROUND Gastric cancer(GC)is a relatively frequent clinical phenomenon,referring to ma-lignant tumors emerging in the gastric mucosal epithelial cells.It has a high mor-bidity and mortality rate,posing a significan...
关键词：NAB-PACLITAXEL Gastric cancer Efficacy Safety 
Bilateral macular edema secondary to nab-paclitaxel therapy for breast cancer
《International Journal of Ophthalmology(English edition)》2024年第10期1963-1966,共4页Zi-Yi Zhou Ya-Ting Ye Jing-Ting Zhu Dong-Jie Sun Yu-Sheng Wang Guo-Rui Dou 
Supported by National Natural Science Foundation of China(No.81970814,No.82371071);Youth Science and Technology Nova Program of Shaanxi Province(No.2016KJXX-19);Xijing Supportive Grant(No.XJZT19ML19).
Dear Editor,Nanoparticle albumin bound(nab)–paclitaxel is a member of the taxane agents that has been proven efficient and widely applied in breast cancer as well as other kind of cancers.The taxane-induced macular e...
关键词：EDEMA BREAST MACULAR 
Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers:An open-label,non-randomized,phase II clinical trial被引量：1
《World Journal of Gastroenterology》2024年第30期3564-3573,共10页Ling-Xiao Xu Jia-Jia Yuan Ran Xue Jun Zhou 
BACKGROUND Biliary tract cancers(BTCs)are a heterogeneous group of tumors with high malignancy,poor prognosis,and limited treatment options.AIM To explore the efficacy and safety of nab-paclitaxel plus capecitabine as...
关键词：NAB-PACLITAXEL CAPECITABINE Biliary tract cancer Objective response rate Phase II clinical trial 
First-line penpulimab(an anti-PD1 antibody)and anlotinib(an angiogenesis inhibitor)with nab-paclitaxel/gemcitabine(PAAG)in metastatic pancreatic cancer:a prospective,multicentre,biomolecular exploratory,phase II trial被引量：5
《Signal Transduction and Targeted Therapy》2024年第7期2960-2969,共10页Huizi Sha Fan Tong Jiayao Ni Yi Sun Yahui Zhu Liang Qi Xiaoqin Li Wei Li Yan Yang Qing Gu Xing Zhang Xiaoxuan Wang Chan Zhu Dongsheng Chen Baorui Liu Juan Du 
National Key Research and Development Program of China(2020YFA0713804);the National Natural Science Foundation of China(82272811);Jiangsu Province Key Research and Development Program(BE2023654);Nanjing Jiangbei New Area Key Research and Development Program,Special Fund of Health Science and Technology Development of Nanjing(YKK20080);Fundings for Clinical Trials from the Affiliated Drum Tower Hospital,Medical School of Nanjing University(2023-LCYJ-PY-29).
Metastatic pancreatic cancer(mPC)has a dismal prognosis.Herein,we conducted a prospective,multicentre,single-arm,phase II trial evaluating the efficacy and safety of penpulimab and anlotinib in combination with nab-pa...
关键词：CA724 PROSPECTIVE centre 
Initial chemotherapy option for pancreatic ductal adenocarcinoma in patients with adequate performance status
《Journal of Pancreatology》2023年第4期196-201,共6页Jiazhang Xing Yuping Ge Xiaolei Gong Yuan Liu Yuejuan Cheng 
Pancreatic ductal adenocarcinoma(PDAC)is a highly progressive lethal malignancy,with chemotherapy being the primary treatment modality.This article provides a review of the initial chemotherapy options for PDAC patien...
关键词：FOLFIRINOX Gemcitabine plus nab-paclitaxel Pancreatic ductal adenocarcinoma 
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
《四川生理科学杂志》2023年第10期1917-1917,共1页Peter Schmid 
Background:Unresectable locally advanced or metastatic triple-negative(hormone-receptor-negative and human epidermal growth factor receptor 2[HER2]-negative)breast cancer is an aggressive disease with poor outcomes.Na...
关键词：BREAST CANCER PACLITAXEL 
Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-na?ve advanced pancreatic ductal adenocarcinoma被引量：2
《Cancer Biology & Medicine》2023年第10期765-778,共14页Zhou Zhu Hui Tang Jinrong Ying Yuejuan Cheng Xiang Wang Yingyi Wang Chunmei Bai 
supported by grants from National High Level Hospital Clinical Research Funding(Grant Nos.2022-PUMCH-D-001 and 2022-PUMCH-A-213)。
Objective:Gemcitabine plus nab-paclitaxel(GnP)is the standard first-line therapy for advanced pancreatic ductal adenocarcinoma(PDAC).S-1,an oral fluoropyrimidine derivative,as compared with gemcitabine,is non-inferior...
关键词：Advanced pancreatic cancer first-line chemotherapy GEMCITABINE S-1 NAB-PACLITAXEL 
Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial被引量：6
《Hepatobiliary Surgery and Nutrition》2023年第1期37-44,共8页Wen Zhang Yongkun Sun Zhichao Jiang Wang Qu Caifeng Gong Aiping Zhou 
Background:This study aimed to evaluate the efficacy and safety of a new combination of nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule(S-1)for patients with advanced biliary tract carcinoma(BTC).Meth...
关键词：Biliary tract adenocarcinoma chemotherapy NAB-PACLITAXEL tegafur gimeracil oteracil potassium capsule(S-1) 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部